Pakistan is considered one of the global epicentres of diabetes, and the prevalence of the disease continues to rise steadily across the country.The country ranks third in the world in terms of the ...

The new treatment offers a median overall survival of 29.3 months for eligible AML patients and 10.3 months for those with intrahepatic cholangiocarcinoma, according to clinical data cited by the comp ...

The company recently received market authorization from the Indian drug regulator for its drug Vorasidenib, a first-in-class, ...

Servier India has received approval from India's drug regulator for Vorasidenib, a new medication for brain cancer in patients with Grade 2 IDH-mutant glioma. This marks a significant advancement, ...

Servier India has received approval for Vorasidenib (Voranigo), adding a second rare-cancer treatment to its portfolio in the ...

French drugmaker Servier is sharpening its India strategy as it looks to bring more first-in-class and precision medicines to the country, deepen its role in global clinical research, and use India as ...

Servier India receives CDSCO approval for Vorasidenib (Voranigo), a brain cancer drug for Grade 2 IDH-mutant glioma patients.

Servier India to launch Vorasidenib (Voranigo), a targeted therapy for patients with Grade 2 IDH-mutant glioma ...

A new study published in Addiction has identified genetic factors that influence both a person’s risk of developing an addiction and their educational attainment. Researchers found that some genetic ...

Servier, an independent international pharmaceutical group governed by a foundation, today announced that Voranigo® (vorasidenib) has been awarded the inaugural 2025 Prix Galien Bridges Award for Best ...

TIBSOVO is a targeted therapy that works against an abnormal protein created by a mutation in the IDH1 gene. This abnormal protein plays an important role in the development of AML because it prevents ...

Under the initiative, a customized panel of biomarker tests for AML—an aggressive blood cancer—and CCA—a rare bile duct cancer—will be made available across India at subsidized rates. The IDH1 and ...